Capricor Therapeutics (GB:0HTB)
UK Market

Capricor Therapeutics Stock Analysis & Ratings

GB:0HTB Stock Chart & Stats

Currently, no data available
Please return soon. This page is being updated.



P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.



What was Capricor Therapeutics’s price range in the past 12 months?
Capricor Therapeutics lowest stock price was €0.00 and its highest was €0.00 in the past 12 months.
    What is Capricor Therapeutics’s market cap?
    Capricor Therapeutics’s market cap is €9.23M.
      What is Capricor Therapeutics’s price target?
      The average price target for Capricor Therapeutics is €17.08. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is €17.08 ,the lowest forecast is €17.08. The average price target represents 4400.27% Increase from the current price of €0.379.
        What do analysts say about Capricor Therapeutics?
        Capricor Therapeutics’s analyst rating consensus is a ‘Moderate Buy. This is based on the ratings of 1 Wall Streets Analysts.
          When is Capricor Therapeutics’s upcoming earnings report date?
          Capricor Therapeutics’s upcoming earnings report date is Aug 11, 2022 which is in 85 days.
            How were Capricor Therapeutics’s earnings last quarter?
            Capricor Therapeutics released its earnings results on May 10, 2022. The company reported -€0.304 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.304.
              Is Capricor Therapeutics overvalued?
              According to Wall Street analysts Capricor Therapeutics’s price is currently Undervalued.
                Does Capricor Therapeutics pay dividends?
                Capricor Therapeutics does not currently pay dividends.
                What is Capricor Therapeutics’s EPS estimate?
                Capricor Therapeutics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Capricor Therapeutics have?
                Capricor Therapeutics has 24,320,000 shares outstanding.
                  What happened to Capricor Therapeutics’s price movement after its last earnings report?
                  Capricor Therapeutics reported an EPS of -€0.304 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same N/A.
                    Which hedge fund is a major shareholder of Capricor Therapeutics?
                    Among the largest hedge funds holding Capricor Therapeutics’s share is Oracle Investment Management Inc. It holds Capricor Therapeutics’s shares valued at N/A.


                      Capricor Therapeutics Stock Analysis

                      The Capricor Therapeutics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                      Learn more about TipRanks Smart Score

                      Company Description

                      Capricor Therapeutics

                      Capricor Therapeutics, Inc. engages in the discovery, development and commercialization of first-in-class biological therapies for the treatment of cardiac and other serious medical conditions. Its product candidate consists of CAP-1002, Cenderitide, Exosomes, CAP-1001, CU-NP and CSps. The company was founded in August 2005 and is headquartered in Beverly Hills, CA.

                      Similar Stocks
                      Price & Change
                      Johnson & Johnson
                      BioLife Solutions
                      Arca Biopharma

                      Popular Stocks

                      What's Included in PREMIUM?
                      Make informed decisions based on Top Analysts' activity
                      Know what industry insiders are buying
                      Get actionable alerts from top Wall Street Analysts
                      Find out before anyone else which stock is going to shoot up
                      Get powerful stock screeners & detailed portfolio analysis